Search results
Showing 331 to 345 of 388 results for hypertension
Polycystic ovary syndrome: metformin in women not planning pregnancy (ESUOM6)
Summary of the evidence on metformin for polycystic ovary syndrome (PCOS) in women not planning pregnancy to inform local NHS planning and decision-making
Evidence-based recommendations on sacubitril valsartan (Entresto) for treating symptomatic chronic heart failure with reduced ejection fraction.
Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (TA217)
Evidence-based recommendations on donepezil (Aricept), galantamine (Reminyl), rivastigmine (Exelon) and memantine (Ebixa) for treating Alzheimer's disease in adults.
This guideline covers diagnosing and managing epilepsy in children, young people and adults in primary and secondary care, and referral to tertiary services. It aims to improve diagnosis and treatment for different seizure types and epilepsy syndromes, and reduce the risks for people with epilepsy.
Show all sections
Sections for NG217
- Overview
- 1 Diagnosis and assessment of epilepsy
- 2 Information and support
- 3 Referral to tertiary specialist services
- 4 Principles of treatment, safety, monitoring and withdrawal
- 5 Treating epileptic seizures in children, young people and adults
- 6 Treating childhood-onset epilepsies
- 7 Treating status epilepticus, repeated or cluster seizures, and prolonged seizures
The AutoPulse non-invasive cardiac support pump for cardiopulmonary resuscitation (MIB18)
NICE has developed a Medtech Innovation Briefing (MIB) on the AutoPulse non-invasive cardiac support pump for cardiopulmonary resuscitation
Evidence-based recommendations on balloon angioplasty with or without stenting for coarctation or recoarctation of the aorta in adults and children. This involves gently inflating a balloon in the narrow area of the aorta to widen it so blood can flow more easily.
View recommendations for IPG74Show all sections
Sections for IPG74
This indicator covers the proportion of young people aged 12 to 18 years with diabetes who have had their blood pressure recorded in the previous 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG69
Interim methods guide for developing service guidance 2014 (PMG8)
Interim methods guide for developing service guidance 2014
NICE has developed a Medtech Innovation Briefing (MIB) on the SpyGlass direct visualisation system for diagnostic and therapeutic procedures during endoscopy of
Therapeutic amnioinfusion for oligohydramnios during pregnancy (excluding labour) (IPG192)
Evidence-based recommendations on therapeutic amnioinfusion for treating oligohydramnios during pregnancy (excluding labour). This involves injecting a substance similar to amniotic fluid into the space around the baby.
View recommendations for IPG192Show all sections
Sections for IPG192
This indicator covers the establishing and maintaining of a register of patients aged 18 or over with a BMI of 27.5 kg/m2 or more (or 30 kg/m2 or more if ethnicity is recorded as White) in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM222
This indicator covers the establishing and maintaining of a register of patients aged 18 or over with a BMI of 23 kg/m2 or more (or 25 kg/m2 or more if ethnicity is recorded as White) in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM221
This guideline covers the main risk factors linked with cardiovascular disease: poor diet, physical inactivity, smoking and excessive alcohol consumption. It aims to reduce the high incidence of cardiovascular disease. This, in turn, will help prevent other major causes of death and illness, such as type 2 diabetes and many cancers.
Psychosis and schizophrenia in children and young people: recognition and management (CG155)
This guideline covers recognising and managing psychosis and schizophrenia in children and young people. It aims to improve early recognition of psychosis and schizophrenia so that children and young people can be offered the treatment and care they need to live with the condition.
This quality standard covers assessing and managing psoriasis in adults, young people and children. It describes high-quality care in priority areas for improvement.
View quality statements for QS40Show all sections
Sections for QS40
- Quality statements
- Quality statement 1: Assessing disease severity
- Quality statement 2: Assessing impact of disease
- Quality statement 3: Referring to specialist services
- Quality statement 4: Assessing cardiovascular risk
- Quality statement 5: Assessing for psoriatic arthritis
- Quality statement 6: Monitoring systemic therapy
- Update information